Codexis, Inc. (CDXS) Stock Price Hits 52-Week High Today

June 8, 2018 - By Winifred Garcia

Codexis, Inc. (NASDAQ:CDXS) Logo

Investors sentiment decreased to 1.34 in Q1 2018. Its down 0.83, from 2.17 in 2017Q4. It is negative, as 9 investors sold Codexis, Inc. shares while 20 reduced holdings. 16 funds opened positions while 23 raised stakes. 28.16 million shares or 0.51% more from 28.02 million shares in 2017Q4 were reported.
Morgan Stanley owns 98,319 shares. Howe Rusling accumulated 0.01% or 5,000 shares. Goldman Sachs Grp Incorporated accumulated 0% or 19,911 shares. Blair William & Il invested in 143,794 shares. Prelude Capital Management Limited Liability Company holds 0.04% or 47,614 shares in its portfolio. State Board Of Administration Of Florida Retirement owns 44,892 shares for 0% of their portfolio. Vantage Inv Limited Liability Corporation reported 0.01% in Codexis, Inc. (NASDAQ:CDXS). Prescott Grp Cap Mgmt Ltd Liability Company invested in 3.11% or 1.30M shares. California State Teachers Retirement System holds 0% of its portfolio in Codexis, Inc. (NASDAQ:CDXS) for 62,120 shares. Trexquant L P has invested 0.01% of its portfolio in Codexis, Inc. (NASDAQ:CDXS). Commercial Bank Of Montreal Can stated it has 1,500 shares or 0% of all its holdings. Voya Mgmt Lc invested in 0% or 18,236 shares. Millennium Ltd holds 0% or 31,698 shares in its portfolio. Gilder Gagnon Howe Ltd Com holds 0.03% of its portfolio in Codexis, Inc. (NASDAQ:CDXS) for 207,873 shares. Citadel Advisors Ltd Liability Co owns 12,507 shares or 0% of their US portfolio.

Since March 21, 2018, it had 0 insider purchases, and 10 selling transactions for $2.84 million activity. 20,000 shares valued at $259,930 were sold by Lalonde James on Monday, May 14. 22,000 shares were sold by Aldridge Michael D., worth $283,945. $464,384 worth of Codexis, Inc. (NASDAQ:CDXS) shares were sold by WOLF DENNIS P. SANGSTER GORDON had sold 18,736 shares worth $264,307 on Thursday, May 24. NICOLS JOHN J sold $259,828 worth of Codexis, Inc. (NASDAQ:CDXS) on Thursday, March 22. The insider Cheng Pam P. sold $549,782.

The stock of Codexis, Inc. (NASDAQ:CDXS) hit a new 52-week high and has $15.85 target or 6.00 % above today’s $14.95 share price. The 6 months bullish chart indicates low risk for the $795.94M company. The 1-year high was reported on Jun, 8 by Barchart.com. If the $15.85 price target is reached, the company will be worth $47.76 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 3.55% or $0.55 during the last trading session, reaching $14.95. About 90,369 shares traded. Codexis, Inc. (NASDAQ:CDXS) has risen 215.91% since June 8, 2017 and is uptrending. It has outperformed by 203.34% the S&P500.

Analysts await Codexis, Inc. (NASDAQ:CDXS) to report earnings on August, 8. They expect $-0.13 earnings per share, 0.00 % or $0.00 from last year’s $-0.13 per share. After $-0.10 actual earnings per share reported by Codexis, Inc. for the previous quarter, Wall Street now forecasts 30.00 % negative EPS growth.

Codexis, Inc. (NASDAQ:CDXS) Ratings Coverage

Among 2 analysts covering Codexis (NASDAQ:CDXS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Codexis has $1600 highest and $11.5 lowest target. $13.75’s average target is -8.03% below currents $14.95 stock price. Codexis had 2 analyst reports since March 12, 2018 according to SRatingsIntel. The company was initiated on Wednesday, May 16 by Stephens. The stock of Codexis, Inc. (NASDAQ:CDXS) has “Buy” rating given on Monday, March 12 by H.C. Wainwright.

More notable recent Codexis, Inc. (NASDAQ:CDXS) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO” on June 01, 2018, also Globenewswire.com with their article: “Codexis Reports First Quarter 2018 Financial Results” published on May 10, 2018, Globenewswire.com published: “Codexis to Present at Three Upcoming Investment Conferences” on May 29, 2018. More interesting news about Codexis, Inc. (NASDAQ:CDXS) were released by: Fool.com and their article: “3 High-Growth Stocks That Are Just Getting Started” published on May 12, 2018 as well as Seekingalpha.com‘s news article titled: “Codexis’ (CDXS) CEO John Nicols on Q1 2018 Results – Earnings Call Transcript” with publication date: May 11, 2018.

Codexis, Inc. discovers, develops, and sells protein catalysts. The company has market cap of $795.94 million. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable clients to perform chemistry screening. It currently has negative earnings. The firm also provides protein catalyst screening and protein engineering services.

Codexis, Inc. (NASDAQ:CDXS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: